Company Profile
Ocular Therapeutix Stock Price, News & Analysis
- Ticker:
- OCUL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.64 USD (+1.59%)
Close
Last updated: July 27, 2026
1.82B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, OCUL closed up 1.59% at $8.64. No new same-company headline was identified in the current news window.
Company overview
Business overview
Ocular Therapeutix is an eye-care company focused on sustained-release therapies and ophthalmic products. Its business is tied to retina, glaucoma, and surgical eye-care applications.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Ocular Therapeutix sits in ophthalmology biotechnology.
Business Model Characteristics
The company depends on product development, commercial execution, and the ability to expand its ophthalmic portfolio.
Position Within the Biotechnology Landscape
Ocular is a specialty-eye-care name whose stock reacts to product adoption and clinical progress.
Future catalysts
Ocular Therapeutix’s next three months are about AXPAXLI and DEXTENZA, especially whether the company can keep moving its wet AMD and retinal-disease franchise toward a clearer regulatory and commercial path. Investors will also watch whether the longer-acting delivery platform keeps differentiating the story from other ophthalmology names.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Ocular Therapeutix
- 02
- 03
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
LENZ · Source: Lenz Therapeutics Inc
- 04
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
KPRX · Source: Kiora Pharmaceuticals
- 05
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Source: Ocular Therapeutix
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ocular Therapeutix (OCUL)?
Ocular Therapeutix (OCUL) most recently closed at 8.64 USD, a +1.59% move versus the previous session.
What is the market cap of Ocular Therapeutix (OCUL)?
Ocular Therapeutix currently has a market capitalization of 1.82B USD on BioPharmSignal.
What does Ocular Therapeutix do?
Ocular Therapeutix is an eye-care company focused on sustained-release therapies and ophthalmic products. Its business is tied to retina, glaucoma, and surgical eye-care applications.
On which exchange is OCUL stock listed?
Ocular Therapeutix (OCUL) is associated with NASDAQ, United States, Biopharma.
What is Ocular?
Ocular Therapeutix’s next three months are about AXPAXLI and DEXTENZA, especially whether the company can keep moving its wet AMD and retinal-disease franchise toward a clearer regulatory and commercial path.
Which conditions is Ocular Therapeutix targeting with Ocular?
Ocular Therapeutix is associated with ophthalmology based on its company overview and current catalyst commentary.
How does Ocular Therapeutix describe recent progress with Ocular?
Ocular Therapeutix’s next three months are about AXPAXLI and DEXTENZA, especially whether the company can keep moving its wet AMD and retinal-disease franchise toward a clearer regulatory and commercial path.
What is Therapeutix?
Ocular Therapeutix is an eye-care company focused on sustained-release therapies and ophthalmic products.